Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

FB 04 - Universitätsmedizin

Johannes Gutenberg-Universität Mainz

Obere Zahlbacher Str. 63, Geb. 912, 55131 Mainz
  • 06131/17-9704 oder 9799 (Sekretariat)
  • 06131/17-9669
Forschungsprojekte
Ergebnisse pro Seite:  10

2025 - 2027

PePCoM (Pectus Pain Comparative Management) bei operativer Korrektur von Brustwandfehlbildungen
  • Dr. Stephan

2025

A Phase 3 randomized, double-masked study comparing theefficacy of EYP-1901 against aflibercept
  • PD Dr. Dr. Katrin

2025

R3918-AMD-2326
  • PD Dr. Dr. Katrin

2025

A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
  • Prof. Dr. Dr. Katrin

2025 - 2026

CRIMSON: A multicentre, randomised, sham-controlled (andactive controlled in the USA), double-masked, 72-week trial tostudy the safety, tolerability, pharmacokinetics, and efficacy of3 dosing regimens of intravitreal BI 764524 in patients withmoderately severe to severe non-proliferative diabeticretinopathy
  • Prof. Dr. Dr. Katrin

2025

SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy
  • PD Dr. Dr. Katrin

2025 - 2026

DX219
  • Prof. Dr. Dr. Katrin

2025 - 2026

A Phase 1b open-label, dose-escalating study evaluating the safety,tolerability, pharmacokinetics, and early signs of biological activity ofdanegaptide following oral administration in participants with diabeticmacular edema
  • Prof. Dr. Dr. Katrin

2025 - 2026

SPECTRUM - An observational study program toinvestigate the effectiveness of aflibercept 8 mg used inDME and nAMD in a real-world setting.
  • PD Dr. Dr. Katrin

2025 - 2027

A Randomized, Multicenter, Double-Masked, Vehicle -Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
  • Prof. Dr. Dr. Katrin